Drugs / huMNC2-CAR44
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04020575 | Jan 2020 → Jan 2025 overdue | breast cancer | Minerva Biotechnologies Corporation | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | huMNC2-CAR44 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04020575 ↗ |
| Modality | Cell therapy | “autologous T cell product” NCT04020575 ↗ |